Public Company Edition: Xilio, Ventyx, MiNK and Context went public in the US and later traded at or above their initial public offering prices. Also, Sarepta raised $500m and Relay grossed $350m in new offerings, while Oncopeptides, Esperion, Zymergen and Ardelyx reorganized and cut jobs.

Indian firms debut empagliflozin copies ahead of expected patent expiry for diabetes blockbuster Jardiance in the country. Spotlight now on how swiftly Boehringer Ingelheim can fend off the entrants and whether the local challenge goes well beyond “inspiration” from the goings-on in the case of another SGLT2 inhibitor dapagliflozin.

Avoro Capital, Holocene Advisors and Darwin Global say that Acceleron should sell later for a higher price based on forthcoming data or Merck should raise its bid above $180 per share.

Janssen Biotech adds to its bispecific antibody pipeline for cancer via pair of collaborations. Ipsen and Accent pair up to investigate new target for acute myeloid leukemia.

The King's College London spin-out has gained £11.5m backing to take its ‘parallel CAR-T’ into the clinic.

Despite multiple challenges including pricing pressures and slowing general economic growth, China offers attractive opportunities for emerging biopharma firms, helped by an encouraging regulatory environment. But weighing up options around challenging areas including partnering is essential, a new report states. 

The Belgian group is the latest to be hit by the FDA's difficulties in address the growing backlog of facility inspections, leaving bimekizumab in limbo in the US, despite having just been approved as Bimzelx in Europe.

The UK major is delighted with the German biotech's decision to throw in the regulatory towel with CVnCoV and concentrate on the firms' collaboration to development a second-generation COVID-19 vaccine. However, GSK is insisting that the partners look at both modified as well as unmodified mRNA approaches, a significant change of strategy for CureVac.

Congress is considering legislation that would reverse some of the Trump administration's friendly corporate tax policies, presenting another challenge to the biopharmaceutical industry.

Company hopes a different formulation of its intracanicular insert of cyclosporin might provide longer duration of drug in the eye and better tear production with it.

The company announced it would withdraw the BLA for balstilimab monotherapy in cervical cancer following Keytruda’s full approval, but it plans to keep developing the drug.

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.